Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Intravitreal Administration Techniques for AAV2-Based Ocular Gene Therapy Safety and Efficacy Studies

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Intravitreal Administration Techniques for AAV2-Based Ocular Gene Therapy Safety and Efficacy Studies

Intravitreal AAV2 Administration for Ocular Gene Therapy Studies

CELL & GENE | RNA | BIOLOGICS

Proven Intelligence Accelerating Next-Generation Therapies.

A senior scientist leads a discussion with a group of diverse junior scientists in a bright, modern laboratory setting.

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

Executive Summary

The technical and operational framework for designing and executing GxP-compliant in vivo safety and efficacy studies for AAV2-based ocular gene therapies requires a focus on intravitreal administration. We detail methodologies for precise vector delivery, non-target tissue biodistribution analysis, and the generation of submission-ready data for both FDA and UK MHRA review. Our approach integrates a tailored preclinical strategy with access to appropriate nonhuman primate models, accelerating program timelines to IND submission within 18-24 months.

Frequently Asked Questions

Question Answer
What makes intravitreal injection a preferred route for some ocular gene therapies? Intravitreal (IVT) injection allows for broad distribution of the AAV vector throughout the vitreous humor, targeting cells in the inner retina, such as retinal ganglion cells. It is a less invasive procedure compared to subretinal administration, which can be a significant factor in clinical translation and patient safety profiles.
How do you assess non-target tissue biodistribution for an ocular therapy? A comprehensive biodistribution assessment is performed by collecting a full range of tissues post-mortem. We use highly sensitive qPCR or ddPCR assays to quantify vector genome copies in both ocular tissues and key systemic organs (e.g., liver, spleen, gonads) to build a complete safety profile for regulatory review.
Which nonhuman primate model is most suitable for AAV2 ocular studies? The cynomolgus macaque is a highly relevant model for ocular gene therapy research. Its eye structure, including the fovea, closely resembles that of humans, providing predictive data on vector efficacy, transduction patterns, and potential immune responses.
Can study data be used for both FDA (US) and MHRA (UK) submissions? Yes. We design IND-enabling toxicology studies to meet global regulatory standards. By aligning study endpoints and data collection with the requirements for both an Investigational New Drug (IND) application and an Investigational Medicinal Product Dossier (IMPD), the resulting data package supports parallel or sequential submissions.

A close-up of a gloved hand handling PCR tubes with blue liquid in a laboratory rack, with a blue color overlay.

A close-up of a Pall Corporation single-use bioreactor system in a cleanroom environment, showing the control panel, vessel with cell culture media, and tubing.

Designing a Tailored Ocular Preclinical Strategy

A standardized testing template does not exist for ocular gene therapies. The unique anatomy and immune-privileged status of the eye demand a preclinical strategy tailored to the specific AAV2 capsid, transgene, and target indication. The objective is to define the therapeutic dose, evaluate transgene expression, and meticulously document any potential inflammatory responses or off-target effects.

Our scientific approach focuses on several key areas:

  • Dose-Ranging Efficacy: Establishing the optimal vector dose that achieves therapeutic levels of transgene expression without inducing significant toxicity.

  • Vector Biodistribution: Quantifying vector spread within the eye and confirming its absence in non-target systemic tissues.

  • Immunogenicity Assessment: Developing phase-appropriate bioanalytical assays to monitor for anti-AAV neutralizing antibodies and cellular immune responses.

  • Functional Outcomes: Utilizing specialized ophthalmic examinations (e.g., electroretinography, optical coherence tomography) to measure functional improvement and monitor retinal health.

High-Fidelity In Vivo Intelligence for Complex Modalities

Executing these studies requires precision. Our >100,000 sq ft facility is equipped for advanced surgical procedures, including intravitreal administration techniques that ensure accurate and reproducible vector delivery. This operational control is foundational to generating reliable data for dose-ranging and toxicology programs conducted under GxP conditions.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is a key scientific collaborator in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

The scientific lineage of our team, which includes leaders from the Gene Therapy Program at the University of Pennsylvania, provides deep experience in overcoming vector-related challenges. Insights from historical work demonstrating sustained efficacy in the face of pre-existing immunity (PMID: 15637142) inform our strategies for managing potential immune responses. Data showing that AAV vectors can achieve high, well-tolerated expression levels (PMID: 32937039) reinforces the importance of precise capsid selection and dose optimization to maximize the therapeutic window.

A 3D rendering of Y-shaped antibody molecules against a blue, abstract background.

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Animal Welfare and NHP Model Selection

The selection of an NHP model with an immune system that closely mirrors human response is a core component of a predictive preclinical program. Our strategic integration with the Bioculture Group provides reliable and timely access to appropriate nonhuman primate models, a key factor in mitigating timeline risks for program sponsors.

Our commitment to animal welfare is governed by AAALAC and USDA standards, strictly adhering to the 3Rs Principle (Replacement, Reduction, and Refinement). We provide enhanced housing conditions and cognitive enrichment programs throughout the in-life phase of every study.

This combination of operational excellence and scientific expertise has supported a 100% successful IND submission rate for programs conducted since 2019 by our scientific leadership, now continuing that legacy since the launch of the Franklin Biolabs brand in 2024.

Technical Visualization: AAV Ocular In Vivo Study Workflow

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities